Capillary electrophoresis study of interaction between omega-3 fatty acids and epigallocatechin gallate by Poleschuk, Carlee Dawn Doris (author) et al.
  
Faculty of Science 
 
CAPILLARY ELECTROPHORESIS STUDY OF INTERACTION BETWEEN OMEGA-3 
FATTY ACIDS AND EPIGALLOCATECHIN GALLATE 
 
2016  |    CARLEE DAWN DORIS POLESCHUK 
B.Sc. Honours thesis 
 
 
Capillary Electrophoresis Study of Interaction between Omega-3 Fatty Acids 
and Epigallocatechin Gallate 
by 
Carlee Dawn Doris Poleschuk 
 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT  
OF THE REQUIREMENTS FOR THE DEGREE OF  
BACHELOR OF SCIENCE (HONS.) 
in the 
DEPARTMENT OF BIOLOGICAL AND PHYSICAL SCIENCES  
(CHEMICAL BIOLOGY) 
 
 
 
 
We accept this thesis as conforming to the required standards: 
 
Kingsley Donkor (Ph.D.), Thesis Supervisor, Dept. Physical Sciences 
 
Naowarat Cheeptham (Ph.D.), Co-supervisor, Dept. Biological Sciences 
 
Dipesh Prema (Ph.D.), Committee Member, Dept. Physical Sciences 
 
 
Dated this 22nd day of April, 2016, in Kamloops, British Columbia, Canada 
 
© Carlee Dawn Doris Poleschuk, 2016 
i 
 
ABSTRACT 
 
Cancer, a global disease affecting millions of people, is characterized by uncontrolled cell 
division due to mutations within the cell. The resulting cell mass continues to rapidly grow, 
resulting in tumours. Epigallocatechin gallate is a polyphenolic catechin found in green tea leaves 
that has been shown to have antioxidant and anti-inflammatory properties. Recently, it has also 
been shown to have anti-cancerous effects on various breast cancer cell lines. The effects include 
inhibiting cancer cell line growth, down-regulating estrogen receptor function, inducing apoptosis, 
inhibiting tumour promotion, and exhibiting antioxidant properties. This shows that 
epigallocatechin gallate is a potential cancer therapeutic agent. Although these are promising in 
vitro results, epigallocatechin gallate does not readily cross the cellular phospholipid bilayer in 
vivo. It is hypothesized that epigallocatechin gallate could be carried through the plasma membrane 
and into the cell when attached to a lipid molecule. The molecule that is currently being tested as 
a carrier molecule is the omega-3 fatty acid docosahexaenoic acid. The analytical technique 
affinity capillary electrophoresis has been used to determine that epigallocatechin gallate and 
docosahexaenoic acid have a reasonably strong interaction of 4.0 (± 1.2) x 104 at physiological 
pH. 
Thesis Supervisor: Associate Professor Dr. Kingsley Donkor 
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1 INTRODUCTION 
 
 The health benefits of green tea are becoming more and more prominent in today’s society. 
The numerous benefits that are typically advertised include lowering cholesterol, inhibiting the 
increase of blood pressure and preventing plaque formation that leads to cavities (the tea spot 
2016). Green tea has also been shown to contain high levels of antioxidant and anti-inflammatory 
properties with loose-leaf green teas having the most benefit (Fujiki 2005). The class of molecules 
responsible for these vast and favourable health benefits are green tea catechins. Catechins account 
for 30-40% of the dry weight of solids in steeped green teas and of the four major polyphenolic 
catechins present in green tea, EGCG, a flaven-3-ol polyphenol, is the most abundant and 
biologically active (Ishii et al. 2008; Ranzato et al. 2014; Zeng et al. 2014).  
 Epigallocatechin gallate (EGCG), shown in Figure 1, has been reported to contain many anti-
cancerous effects. It prevents cancer formation by exhibiting antioxidant properties such as 
neutralizing radical oxygen species before they induce cell mutations that lead to tumours (Ishii et 
al. 2007). It also down-regulates estrogen receptor alpha function that normally controls the growth 
of breast cancers (Lee et al. 2012). EGCG has also been shown to induce apoptosis of cancerous 
cells and inhibit tumour promotion (Fujiki 2005; Farabegoli et al. 2007; Ishii et al. 2008). Because 
of these many anti-cancerous effects, ECGC has been determined to be a possible therapeutic agent 
for cancer treatments.  
 
Figure 1. The chemical structure of epigallocatechin gallate, a green tea catechin that has been 
shown to exhibit antioxidant properties, down-regulate estrogen receptor alpha function, induce 
apoptosis and inhibit tumour promotion (Farabegoli et al. 2007; Feng 2006; Fujiki 2005; Ishii et 
al. 2008; Lee et al. 2012). 
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 Cancer is a global disease affecting millions of people on a daily basis. It is characterized as 
uncontrolled cell division due to mutations within the cell (National Cancer Institute 2016). The 
resulting cell mass then continues to rapidly grow resulting in tumours. Of all cancers affecting 
women, breast cancer is the most common in developed countries (excluding non-melanoma skin 
cancers). It is also the second leading cause of death from cancer in Canadian women (Canadian 
Cancer Society 2016). Recent research aims to identify new therapeutic possibilities for breast 
cancer that includes using EGCG.   
 Zeng and colleagues (2014) investigated the effects of therapeutic EGCG on various breast 
cancer cell lines. They determined that physiological concentrations of EGCG inhibited growth in 
estrogen receptor (ER) positive MCF-7 cells by increasing regulation of tumour suppressing genes 
p53/p21. It also significantly increased cell death in the aggressive ER negative cell line MDA-
MB 231. Therapeutics with a potential of targeting MDA-MB 231 cell lines are extremely 
important as this cell line is extremely aggressive, has poor prognosis and does not respond to 
common therapies due to its triple negative characteristic (Holliday and Speirs 2011). 
 Other research conducted by Ranzato and colleagues (2014) also used EGCG as a therapeutic 
agent with the breast carcinoma cell line MCF-7. Calcium is essential in cell survival, proliferation 
and growth and disruption of intracellular calcium normally leads to cell death. They showed that 
EGCG induces a [Ca2+] spike by targeting Ca2+ channels, thus suggesting that EGCG deregulates 
[Ca2+] and leads to decreased MCF-7 viability (Ranzato et al. 2014). Although these in vitro results 
are promising, EGCG is not readily absorbed into the body since it cannot easily cross the 
phospholipid bilayer (Epstein 2009). However, the therapeutic properties of this catechin may be 
applicable to humans if it was carried through the plasma membrane via a carrier molecule. Carrier 
molecules that would be considered are molecules that can easily cross the phospholipid bilayer 
and enter the cancerous cells. These include lipid molecules such as various omega-3 fatty acids.   
 Omega-3 fatty acids are essential nutrients that can be found in many dietary foods such as 
fish oils, flax seeds, eggs, milk and cheese. The body readily absorbs them because they are not 
endogenously produced (Scarsi et al. 2015). This is an advantage of omega-3 fatty acids as opposed 
to other potential lipid carriers. Docosahexaenoic acid (DHA) is an omega-3 fatty acid that has a 
structure of 22:6n-3, shown in Figure 2. DHA can be obtained by eating cold-water fish and from 
ingesting fish oil supplements. DHA is vital for the growth and cognitive function of the adult 
brain and is absolutely essential in the brain development of children and is obtained by breast 
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milk (Horrocks and Yeo 1999). Dietary DHA appears to reduce the risk of heart disease, arthritis, 
and cognitive and behavioural diseases (Kiruthika 2015; Crauste 2016).  Structurally, DHA is a 
highly unsaturated derivative of alpha-linolenic acid (ALA) (Bougnoux et al. 2010). Although 
DHA is an ALA derivative, it is not easily converted to DHA in the body; therefore, it must be 
ingested separately by consuming cold-water fish and fish oil supplements (Horrocks and Yeo 
1999; Kiruthika 2015).  
 
Figure 2. The chemical structure of docosahexaenoic acid, an omega-3 fatty acid that is readily 
obtained in the diet from cold-water fish (Scarsi et al. 2015).   
 
 Recently, the effectiveness of DHA as an addition to common cancer treatments has been 
studied, specifically in breast cancer treatments. It has been shown to have the potential to increase 
cancer treatment efficience without serious or aversive side effects (Bougnoux et al. 2010). 
Research conducted by Hardman and colleagues (2001) determined that rats with xenographs of 
the triple negative breast cancer cell line MDA-MB 231 were more susceptible to anti-cancer 
agents that resulted in tumour shrinkage when supplemented with 0.7 grams of DHA on a daily 
basis (Hardman et al. 2001). These results show that diet may influence or play a significant role 
in the effectiveness of cancer treatment. 
 Overall, EGCG and DHA, and their therapeutic effects on breast cancer, have been studied 
separately, however there is very little in the literature about their interactions. Therefore, by 
studying the interaction of this EGCG with DHA, we may be able to determine a method that 
would allow EGCG to have increased permeability to the plasma membrane and thus increase the 
subsequent effects as a cancer therapeutic agent. An efficient, cheap and time effective analytical 
method for studying the interaction of these two molecules is capillary electrophoresis.  
 Capillary electrophoresis (CE) is an analytical method that differentiates and separates 
charged species on the basis of mobility under the influence of an electric field gradient (Chu et 
al. 1995). When voltage is applied, electroosmotic flow (EOF) is generated through the buffer 
solution along the capillary. The sample is then injected into the buffer and is separated and 
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analyzed based on size and charge. Therefore, small positive ions are detected before small 
negatively charged ions. This process can be seen below in Figure 3.  
 
Figure 3. A diagram depicting EOF including the separation of ions based on size and charge 
between the anode and cathode (Laboratoire Suisse d’Analyse du Dopage 2008). 
 
 Non-covalent molecular interactions, such as the suspected interaction of EGCG and DHA, 
can be quantified using a sub-category method of CE called affinity capillary electrophoresis 
(ACE). In ACE, the electrophoretic mobility is measured as a function of concentration that a 
ligand binds the analyte in the electrophoresis buffer (Chu et al. 1995). As the molecules interact 
inside the capillary, a complex is formed which results in slower migration throughout the capillary 
and a longer migration time to the detector. The binding constant can then be estimated by the 
changes in the migration time of the analyte alone compared to the migration time of the complex. 
In order to determine the change in migration time, a neutral marker is also needed. This compound 
has no effect on the binding affinity and serves as a reference point when calculating the effective 
electrophoretic mobility is used to generate the binding constant of EGCG and DHA. The formula 
for the effective electrophoretic mobility can be seen below in Figure 4.  
 
 
 
 
 
 
Figure 4. The formula and constants for the effective electrophoretic mobility that is used to 
quantify binding interactions (Harris 2010). 
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In this experiment, the capillary will be filled with buffer solution containing varying amounts of 
DHA with a sample solution at a constant concentration of EGCG. It is expected to see larger 
EGCG peak shifts with increasing concentrations of DHA. The binding constant can then be 
estimated by the changes in migration time of EGCG as a function of DHA. This interaction study 
will be optimized for physiological conditions in order to infer the results to possible therapeutic 
approaches for breast cancer.  
2 MATERIALS AND METHODS 
2.1 Reagents  
 The EGCG standard, the DHA standard, dimethylformamide (DMF) and sodium 
tetraborate were all purchased from Sigma-Aldrich Canada Ltd., Oakville, Ontario, Canada and 
were all of analytical-reagent grade. The pH of the sodium borate buffers and background 
electrolyte (BGE) solutions were adjusted by using 1.0 M hydrochloric acid (HCl) and 1.0 M of 
sodium hydroxide (NaOH). All solutions were prepared using filtered 18 MΩ water and were 
filtered once again using a 0.45 µm nylon filter before use in the instrument.  
2.2 Capillary Electrophoresis 
 All of the experiments were performed using a Beckman P/ACE™ MDQ Capillary 
Electrophoresis System (Beckman Coulter, Inc., Fullerton, CA) equipped with an ultraviolet (UV) 
detector and interfaced to a shared lab computer. Uncoated fused-silica capillary (50 µm internal 
diameter, 50 cm total length, 40 cm effective length) was used and purchased from Polymicro 
Technologies (Pheonix, AZ). Galden® HT-110 perfluoropolyether coolant (Ideal Vacuum 
Products LLC, Albuquerque, NM, USA) was used in the capillary cartridge to keep the 
temperature at a consistent 25 °C. Detection was set at a wavelength of 214 nm. This wavelength 
is within the ultraviolet range, which is absorbed by the conjugated double bonds of the EGCG 
molecule and, to a much lesser degree, by the excess pi electrons in the DHA molecule.     
 Initially, the capillary was conditioned by flushing 1.0 NaOH through the capillary for 60 
minutes, 0.1 M NaOH for 30 min and 18 MΩ water for 10 min. Prior to the sample injection of 
each run, the capillary was rinsed for 5 minutes with 0.1 M NaOH, 18 MOhm water for 1 min and 
the run buffer for 4 min. The sample solutions were then injected into the capillary for 5.0 seconds 
with a pressure of 1.0 psi. Separation of the samples occurred under normal polarity at an applied 
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voltage of 10 kV. Each run was allowed to separate for 20 min, with the total time for each run 
being 30 min.   
2.3 Preparation of the EGCG and DHA Stock Solutions 
A 1000 ppm stock solution of EGCG was prepared by dissolving 5 mg in 5 mL of filtered 
18 MΩ water. The stock solution was placed in a glass vial and stored in the fridge at 4oC. A 1000 
ppm stock solution of DHA was also prepared by combining 53 µL DHA into 50 mL of filtered 
methanol. The DHA stock solution was transferred to a brown glass container, as the solution is 
light sensitive. It was also stored in the fridge at 4oC. All stock solutions were filtered again using 
a 0.45 µm nylon filter prior to transfer into their storage containers.  
2.4 Preparation of Buffer and Background Electrolyte Solutions  
A 100 mM stock solution of sodium borate buffer was prepared by dissolving an 
appropriate amount of sodium tetraborate into filtered 18 MΩ water. The pH of each buffer 
solution was then adjusted using a pH reader and either 1.0 M HCl or 1.0 M NaOH. A total of 
three buffer solutions were made with pH’s of 9.0, 8.5 and 8.0 and one BGE solution was made 
with a pH of 7.5.  
2.5 Preparation of Run Buffer and EGCG Samples with DMF 
The 100 mM borate buffer solution was subsequently diluted to 25 mM borate buffer 
solution by transferring 250 µL into the CE vial. Filtered 18 MΩ water was then added to each 
vial to dilute the buffer solution. Various amounts of the 1000 ppm DHA stock solution (0-250 
µL) were then added to the vials to equal 0-250 ppm. Each CE vial had a total of 1 mL and were 
vortexed well. For the samples, 40 µL of the 1000 ppm EGCG stock solution were added to each 
sample vial, along with 5 µL of a 1:50 DMF solution. Filtered 18 MΩ water was then added to 
each vial to equal 400 µL and each sample was vortexed well.  
3 RESULTS AND DISCUSSION 
  
Prior to conducting the interaction study between EGCG and DHA, many instrumental and 
experimental parameters had to be optimized. These conditions included the sodium borate buffer 
and BGE concentration, the concentration of EGCG and the neutral marker.  
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3.1 EGCG Concentration Optimization 
First, the optimal concentration of EGCG was determined. This concentration is important, 
as it will form a complex with the DHA present in the BGE solution. In this experiment, various 
concentrations of EGCG (50-150 ppm) were analyzed at a 50 mM BGE solution, as seen below in 
Figure 5. This work was conducted prior to buffer optimization and the concentration was chosen 
based on previous studies. A 1 µL aliquot of DMF was added to each sample vial prior to running. 
The EGCG peaks appear much smaller than the neutral marker peak because of the large quantity 
of neutral marker added to the EGCG sample. Based on the observed peaks, 100 ppm was selected 
as the constant EGCG concentration to use in the interactions studies. This also confirms the 
concentration of previous studies.  
 
Figure 5. The electropherogram showing various concentrations of EGCG peaks. The top run 
contained 50 ppm (A), the middle contained 100 ppm (B) and the bottom contained 150 ppm (C). 
The first peak is the neutral marker (DMF) and the second smaller peak is the EGCG. Conditions: 
detection, UV; applied voltage, 10 kV; BGE concentration, 50 mM; BGE pH, 7.5; temperature, 
25oC. 
 
3.2 Neutral Marker Optimization 
The use of a neutral marker is essential when using ACE and serves many purposes. First, 
it gives an indication of EOF rate and allows for easy observation of any differences of EOF that 
A 
B 
C 
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may occur across runs. It also serves as a reference point to determine the migration shift of the 
EGCG and DHA complex peak. Optimization of the amount to add of the neutral marker is 
important because it should be detectable and proportional to the EGCG peak. Mesityl oxide and 
DMF were both tested as potential neutral markers. In this experiment, 1 µL of each were added 
to the EGCG sample vials and their peaks were observed as seen in Figure 6. The height of the 
mesityl oxide peaks appeared to greatly decrease over the course of the entire experiment. This 
indicates that it is not very stable and therefore was not chosen for further experiments. DMF, 
however, showed excellent peak heights consistent over the entire run. Therefore, DMF was used 
in the following experiments. For these experiments, a 5 µL aliquot of a 1:50 DMF dilution was 
used in order to obtain appropriate peak heights relative to the EGCG peak.  
 
Figure 6. The electropherogram that compares the two potential neutral markers. The top three 
peaks consisted of a 1 µL aliquot added to samples containing 50 ppm (A), 100 ppm (B) and 150 
ppm (C) of EGCG. The bottom three peaks consisted of a 1 µL aliquot also added to samples 
containing 50 ppm (D), 100 ppm (E) and 150 ppm (F) of EGCG. Based on this data, DMF was 
used as the neutral marker for the following interaction studies. Conditions: detection, UV; applied 
voltage, 10 kV; BGE concentration, 50 mM; BGE pH, 7.5; temperature, 25oC. 
 
3.3 BGE Concentration Optimization 
The BGE concentration is a very important factor when using CE. It affects the EOF, and 
can also influence the degree of analyte separate and detection. Initially, four different 
B 
C 
D 
E 
F 
A 
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concentrations were tested in order to determine the concentration that gave the best EGCG peak 
shape and baseline separation. These concentrations included 25 mM, 50 mM, 75 mM and 100 
mM. The optimal BGE concentration was tested at pH 7.5 in order to apply to physiological pH. 
As seen below in Figure 7, the optimal BGE concentration appeared to occur at 25 mM. This 
concentration had the shortest separation time between the neutral marker and the EGCG peaks, 
which is beneficial because once the EGCG complexes with the DHA, it will migrate further from 
the neutral marker. If the baseline separation between these two peaks is large without the addition 
of DHA, then the run time would have to be greatly increased. The 25 mM concentration also gave 
the best EGCG peak shape compared to the other concentrations. The EGCG peak can be seen to 
decrease in sharpness and height as the concentration increases until it completely disappears in 
the 100 mM concentration.  
 
Figure 7. The electropherogram displaying the various BGE concentrations at pH 7.5. Each run 
was run in duplicates at the concentrations of 25 mM (A), 50 mM (B), 75 mM (C) and 100 mM 
(D). The first peak is the neutral marker (DMF) and the second peak is the EGCG (100 ppm). 
Based on the obtained results, 25 mM appeared to give the best EGCG peak shape and baseline 
separation. Therefore, this concentration was used for all following interaction studies. Conditions: 
detection, UV; applied voltage, 10 kV; BGE pH, 7.5; temperature, 25oC. 
 
A 
B 
C 
D 
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3.4 Interaction Studies  
Once the experimental conditions were optimized, experiments that determined the 
interaction between EGCG and DHA were conducted. Because the goal of this work is to observe 
the interaction mimicking physiological conditions, studying the interaction at physiological pH 
was essential. A similar trend is seen in all of the following interaction studies – as the 
concentration of DHA increases in the migration of the EGCG complex peak increases as well. 
This shows that a complex is being formed between EGCG and DHA. The changes in migration 
can then be used to calculate the binding constant between these two molecules. Another trend that 
is seen in every interaction study is a slight migration of the neutral marker peak. This occurs due 
to an increase of viscosity in the BGE solution as the concentration of DHA increases. This 
migration can be corrected for in the binding constant calculations.     
3.4.1 Interaction Study at pH 9.0 
The first interaction study was run with a BGE solution of pH 9.0. This pH was chosen because 
it is an optimal pH to use with a sodium borate buffer and similar work has previously been 
successful at this pH. The results of the interaction study can be seen in Figure 8.  
 
Figure 8. The electropherogram of the interaction study between EGCG and DHA with a 25 mM 
BGE solution of pH 9.0. The sample consisted of a 5 µL aliquot of a 1:50 DMF dilution as well as 
a constant concentration of 100 ppm EGCG. The 25 mM BGE solution contained various 
concentrations of DHA: 0 ppm (A), 50 ppm (B), 100 ppm (C), 150 ppm (D), 200 ppm (E), 250 
ppm (F). The formation of a complex as the concentration of DHA increases is evident due to the 
A 
B 
C 
D 
E 
F 
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increase in migration of the EGCG peak. Conditions: detection, UV; applied voltage, 10 kV; BGE 
concentration, 25 mM; temperature, 25oC. 
 
3.4.2 Interaction Study at pH 8.5 
The second interaction study was run with a BGE solution of pH 8.5. The results of the 
interaction study can be seen below in Figure 9.  
 
Figure 9. The electropherogram of the interaction study between EGCG and DHA with a 25 mM 
BGE solution of pH 8.5. The sample consisted of a 5 µL aliquot of a 1:50 DMF dilution as well as 
a constant concentration of 100 ppm EGCG. The 25 mM BGE solution contained various 
concentrations of DHA: 0 ppm (A), 50 ppm (B), 100 ppm (C), 150 ppm (D), 200 ppm (E), 250 
ppm (F). The formation of a complex as the concentration of DHA increases is evident due to the 
increase in migration of the EGCG peak. Conditions: detection, UV; applied voltage, 10 kV; BGE 
concentration, 25 mM; temperature, 25oC. 
 
3.4.3 Interaction Study at pH 8.0 
The third interaction study was run at a with a BGE solution of pH 8.0. The results of the 
interaction study can be seen below in Figure 10.  
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Figure 10. The electropherogram of the interaction study between EGCG and DHA with a 25 mM 
BGE solution of pH 8.0. The sample consisted of a 5 µL aliquot of a 1:50 DMF dilution as well as 
a constant concentration of 100 ppm EGCG. The 25 mM BGE solution contained various 
concentrations of DHA: 0 ppm (A), 50 ppm (B), 100 ppm (C), 150 ppm (D), 200 ppm (E), 250 
ppm (F). The formation of a complex as the concentration of DHA increases is evident due to the 
increase in migration of the EGCG peak. Conditions: detection, UV; applied voltage, 10 kV; BGE 
concentration, 25 mM; temperature, 25oC. 
 
3.4.4 Interaction Study at pH 7.5  
The fourth interaction study was run at a with a BGE solution pH of 7.5. The results of the 
interaction study can be seen below in Figure 11. Based on these results, an interaction does occur 
between EGCG and DHA at physiological pH.  
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Figure 11. The electropherogram of the interaction study between EGCG and DHA with a 25 mM 
BGE solution of pH 8.0. The sample consisted of a 5 µL aliquot of a 1:50 DMF dilution as well as 
a constant concentration of 100 ppm EGCG. The 25 mM BGE solution contained various 
concentrations of DHA: 0 ppm (A), 50 ppm (B), 100 ppm (C), 150 ppm (D), 200 ppm (E), 250 
ppm (F). The formation of a complex as the concentration of DHA increases is evident due to the 
increase in migration of the EGCG peak. Conditions: detection, UV; applied voltage, 10 kV; BGE 
concentration, 25 mM; temperature, 25oC. 
 
Based on these results, it appears that an interaction does occur between EGCG and DHA at 
physiological pH. This study was run in duplicates in order to obtain enough data to derive a 
significant binding constant.  
3.5 Binding Constant  
The binding constant between the molecules EGCG and DHA was calculated from the data 
obtained from the pH 7.5 experiments. It was analyzed using the linear regression method as 
outlined in detail in the appendix. From this the x-reciprocal, the y-reciprocal and the double 
reciprocal plots were obtained. The plots had R2 values of 0.8585, 0.9997 and 0.8548, respectively. 
From these plots, the equation of the lines were used to calculate the binding constants. The 
calculations that were used can be found in the appendix. The binding constants from the x-
reciprocal, y-reciprocal and double reciprocal were determined to be 4.41 x 104, 4.92 x 104 and 
2.65 x 104, respectively. These values gave an average binding constant value of 4.0 x 104 (±1.2 
x 104), as seen in Table 1. This value implies that there is a reasonably strong interaction between 
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EGCG and DHA at physiological pH. This value is also very close to previous work that 
determined the binding constants of fatty acids with beta-cyclodextrin (Parker and Stalcup 2008).    
Table 1. The binding constants determined for EGCG and DHA at pH 7.5 that were calculated 
using linear regression plots. 
Plot Binding Constant 
X-Reciprocal 4.41 x 104 
Y-Reciprocal  4.92 x 104 
Double Reciprocal 2.65 x 104 
Average 4.0 (±1.2) x 104 
 
As seen in the appendix, all three linear regression plots resulted in large and significant 
R2 values that were greater than 0.85. Because ACE assumes a 1:1 binding system, the binding 
stoichiometry cannot be confirmed unless further analysis is conducted. However, the benefit of 
using the linear regression model over other models to derive binding constants is that the binding 
stoichiometry can be inferred from the x-reciprocal plot. A linear plot is indicative of a 1:1 binding 
stoichiometry compared to a nonlinear plot that may imply a 1:2 binding stoichiometry. In this 
experiment, I would expect a 1:1 binding stoichiometry of EGCG and DHA based on the x-
reciprocal plot.  
4 CONCLUSION AND FUTURE WORK 
 
ACE was shown to be a successful technique for studying the interaction between EGCG 
and DHA at physiological conditions. By using optimized instrumental conditions for ACE 
(detection, UV; applied voltage, 10 kV; BGE concentration, 25 mM; BGE pH, 7.5; temperature, 
25oC), the strength of the interaction between EGCG and DHA could be determined. With these 
conditions, the migration times for the EGCG peak and the EGCG/DHA complex peak were 
measured and analyzed. They were analyzed using the linear regression method (outlined in the 
appendix) that assumes a 1:1 binding system. At physiological pH the binding constant was 
determined to be 4.0 (± 1.2) x 104 by using the linear regression method. This binding constant 
value indicates that a reasonably strong interaction occurs between EGCG and DHA at 
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physiological pH and 25oC. Also, based on the linear plot obtained from the x-reciprocal plot 
shown in the appendix, I would assume a 1:1 binding stoichiometry between EGCG and DHA. 
Therefore, DHA can be selected as a potential carrier molecule that would bind and subsequently 
transport EGCG through the plasma membrane and into the cancerous cell. More investigation 
into the specifics of this interaction must be studied in order to determine the potential of this 
cancer therapeutic strategy.  
Future work for this research would be to run the triplicate of the interaction study with a 
BGE solution of pH 7.5 in order to obtain more statistically significant results. Also, the type of 
interaction should be determined by conducting a thermodynamic study. Because we want to study 
this interaction as close to physiological conditions as possible, the temperature the interaction 
occurs at should be modified to 37oC (the temperature inside the body). The sites of binding should 
also be investigated because ACE assumes a 1:1 interaction. This can be done either by capillary 
electrophoresis-frontal analysis or by studying proton nuclear magnetic resonance (1H-NMR). 
Finally, other Omega-3 fatty acids should be investigated with these instrumental conditions such 
as ALA.   
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6 APPENDIX 
6.1 Linear Regression Method for Calculating Binding Constants  
During the formation of the EGCG and DHA complex, a rapid equilibrium is occurring 
that favours the formation of the complex. The complex occurs in a 1:1 stoichiometry that can be 
seen in Equation 1.  EGCG + DHA ⇌ EGCGDHA    (1) 
The binding constant (K) is then calculated in Equation 2 as follows:  
K = [EGCGDHA][EGCG][DHA]    (2) 
The electrophoretic mobility (µe), discussed in the intro, can then be calculated using Equation 3. 
µe = �LtLdV �1tc − 1tm�� �IoI �     (3) 
Equation 3 can also be given as Equation 4 to determine the electrophoretic mobility of the free 
analyte, μo, given in Equation 5, as well as the electrophoretic mobility of the complex, μc in 
Equation 6.  
µe =  µo +  µcK[DHA]1 +  K[DHA]     (4) 
µo = LdLtVto     (5) 
µc = LdLtVtc     (6) 
Finally, the electrophoretic mobility equation can be rearranged to give three linear equations. 
These linear equations are then used to plot the double reciprocal (Equation 7), the y-reciprocal 
(Equation 8) and the x-reciprocal (Equation 9).  1
µe −  µo =  1�µc  −  µo�K ·  1DHA + 1µc −  µo     (7) 
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[DHA]
µe −  µo =  1�µc  −  µo�  · [DHA] +  1�µc  −  µo�K    (8) 
µe −  µo[DHA] =  −K�µe −  µo� +  K �µc −  µo�    (9) 
For the double reciprocal, the values of  1
µe− µo are plotted against 1DHA and the binding constant is 
calculated by dividing the y-intercept by the slope of the equation. For the y-reciprocal, the [DHA]
µe− µo 
values are plotted against the [DHA]. The y-reciprocal binding constant is then calculated by 
dividing the slope of the equation by the y-intercept. Lastly, the x-reciprocal is plotted with µe− µo[DHA]  
values against �µe −  µo� values. This binding constant is then determined by taking the negative 
of the slope of the equation. All of the binding constant values can then be averaged to obtain a 
significant binding constant value.  
6.2 Linear Regression Plots  
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